Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial
Table 4
MACE at 90 days after PCI in the Danlou Tablet and placebo groups.
Incidence
Treatment difference (%)
Danlou Tablet group
Placebo group
Difference of incidence (95% CI)
value
Full-analysis set
Total MACE, (%)
26 (23.9)
41 (37.3)
1.9 (1.1, 3.4)
0.0
Cardiac death, (%)
0
1 (0.9)
1.0
Nonfatal MI, (%)
24 (22.0)
38 (34.5)
1.9 (1.0, 3.4)
0.0
Target vessel revascularization, (%)
2 (1.8)
5 (4.5)
2.5 (0.5, 13.4)
0.4
Rehospitalization due to CV, (%)
0
0
Per-protocol analysis set
Total MACE, (%)
25 (23.8)
35 (34.0)
1.6 (0.9, 3.0)
0.
Cardiac death, (%)
0
1 (1.0)
0.5
Nonfatal MI, (%)
23 (21.9)
32 (31.1)
1.6 (0.9, 3.0)
0.
Target vessel revascularization, (%)
2 (1.9)
5 (4.9)
2.6 (0.5, 13.9)
0.2
Rehospitalization due to CV, (%)
0
0
CI, confidence interval; CVE, cardiovascular events; MACE, major adverse cardiac event; and MI, myocardial infarction. ifference of incidence = Danlou Tablet − placebo. ardiovascular events included severe angina or heart failure (NYHF ⩾ IV). value is from the continuity-adjusted Chi-square test. value is from Fisher’s exact test.
